title: Occurrence of a Ki-1-positive anaplastic large-cell lymphoma in a patient with Ph' positive chronic myelogenous leukemia successfully treated by alpha-interferon.
abstract: We describe a patient with Philadelphia-chromosome-positive (Ph' +) chronic myelogenous leukemia (CML), who developed an anaplastic large cell lymphoma (ALCL) with T-phenotype, after 43 months successful treatment with alpha-interferon (IFN). Characterization studies of lymphoma cells showed positivity for Ki-1 monoclonal antibody, T-cell surface markers, T-cell receptor beta chain rearrangement, and germline configuration of the BCR gene. At the time of lymphoma diagnosis, the patient had achieved complete hematologic remission from CML with partial karyotypic conversion (50% Ph' + cells). After twelve weekly courses of polychemotherapy, he obtained complete remission from lymphoma. At present, five years from CML diagnosis, the patient has a remarkably stable disease, being in remission from lymphoma and in well controlled CML chronic phase. Our case thus represents the first well documented description of a T-cell non-Hodgkin's lymphoma developed during the course of CML.
authors.affiliation: Department of Human Biopathology, University La Sapienza, Rome, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Montefusco
authors.forename: F
authors.initials: F
authors.lastname: Lo Coco
authors.forename: V L
authors.initials: VL
authors.lastname: Burgio
authors.forename: B
authors.initials: B
authors.lastname: Rondinelli
authors.forename: G
authors.initials: G
authors.lastname: Di Giorgio
authors.forename: M
authors.initials: M
authors.lastname: Mancini
authors.forename: D
authors.initials: D
authors.lastname: Diverio
authors.forename: A
authors.initials: A
authors.lastname: Andriani
authors.forename: G
authors.initials: G
authors.lastname: Avvisati
authors.forename: G
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy / Q000473:pathology*; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary; D011994:Recombinant Proteins; D012074:Remission Induction
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins